LUND, Sweden, March 18, 2025 /PRNewswire/ — Oncorena is pleased to announce that the FDA has approved the Company’s IND application to initiate the Phase I/II study Oncorella-1: A Phase 1/2, open label, single arm study on safety, tolerability and anti-tumor efficacy of orellanine…
